Patents Examined by Layla D Berry
  • Patent number: 10441564
    Abstract: The present invention provides a fructose analogue and a composition thereof which can be used for cancer treatment, has a targeting effect and has little effect on normal cells, particularly when used in the treatment of acute myeloid leukemia (‘AML’) and pancreatic cancer and other types of cancer having similar metabolic characteristics. In the present invention, the fructose analog is selected from the group consisting of 2,5-anhydro-D-mannitol and the 2,5-anhydro-D-mannitol derivative substituted at the 1-position or 6-position by an amino group, an alkyl group or an aryl group, anhydro-D-mannitol tetraacetate and 2,5-anhydroglucitol and the like. The fructose analogs of the present invention can be used to prepare and treat cancer drugs and can be prepared as injectable preparations or oral preparations. The fructose analogues of the present invention can be used in combination with conventional anticancer drugs when used in the preparation of a medicament for the treatment of cancer.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 15, 2019
    Inventors: Wei Jia, Wenlian Chen
  • Patent number: 10426790
    Abstract: The present disclosure provides methods of treating eye allergies and allergic conjunctivitis with cyclodextrin. Ophthalmic compositions of cyclodextrin for topical administration are also provided.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 1, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Scott Young, Todd Brady, Stephen Gitu Machatha, David Clark, Susan Macdonald
  • Patent number: 10420788
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 24, 2019
    Assignee: ALIOS BIOPHARMA, INC.
    Inventors: Guangyi Wang, David Bernard Smith, Leonid Beigelman, Jerome Deval, Marija Prhavc
  • Patent number: 10421771
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 24, 2019
    Assignee: ALIOS BIOPHARMA, INC.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Jerome Deval, Marija Prhavc
  • Patent number: 10414830
    Abstract: The present application provides crystalline forms of 6-per-deoxy-6-per-chloro-?-cyclodextrin, and polymorphs thereof. The present application also provides methods for preparing said polymorphs by dissolving 6-per-deoxy-6-per-chloro-?-cyclodextrin in dimethylformamide and using an anti-solvent of a water/alcohol mixture.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: September 17, 2019
    Assignee: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Shivaji Haribhau Shelke, Shridhar Reddy, Nitin Kumar, Madan Singh
  • Patent number: 10412976
    Abstract: Described herein are products comprising a xylose (e.g., D-xylose or L-xylose and another sweetener such as glucose). Exemplary products include cosmetic products, oral care products, therapeutic products, nutraceutical products, diagnostic, beverages, animal food products, and human food products. Methods of making the xylose containing products from biomass is provided.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 17, 2019
    Assignee: XYLECO, INC.
    Inventor: Marshall Medoff
  • Patent number: 10414829
    Abstract: The present application provides an improved process for the preparation of sugammadex which comprises the halogenation of ?-cyclodextrin in a suitable organic solvent to give 6-per-deoxy-6-per-halo-?-cyclodextrin, wherein halo is bromo or chloro, reacting the halogenated ?-cyclodextrin with 3-mercaptopropionic acid in the presence of alkoxide base to obtain sugammadex of formula I. This application also provides isolation of 6-per-deoxy-6-per-chloro-?-cyclodextrin as a crystalline compound and its use for the preparation of sugammadex of formula (I).
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: September 17, 2019
    Assignee: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Dominik Heckmann
  • Patent number: 10414786
    Abstract: A construct of the structure F—S1-S2 where: F—S1 is an aminoalkylglycoside where F is ?-D-galactopyranosyl-(1?4)-?-D-galactopyranosyl-(1?4)-?-D-glucopyranoside and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: September 17, 2019
    Assignee: KODE BIOTECH LIMITED
    Inventors: Nicolai Bovin, Lissa Gilliver, Stephen Henry, Elena Korchagina
  • Patent number: 10414833
    Abstract: The present disclosure relates to a biocompatible composition and a method for preparing the same, and a hybrid composition of ?-glucan and hyaluronic acid is prepared by hybrid cross-linkage. The biocompatible composition of the present disclosure high stability against heat and bio-enzymes, and thus is capable of being used as a medical material.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: September 17, 2019
    Assignee: INNO PHARM CO., LTD.
    Inventors: Jae Young Lim, Byoung-Chull Chung
  • Patent number: 10406171
    Abstract: The present invention is synergistic antibiotic compositions having pH adjusted profiles for manufacturing combination, and administration, particularly for patients at risk or suffering from ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic compositions containing fosfomycin and aminoglycosides having individually predetermined and selected pH ranges are manufactured and stored for in combination prior to aerosolization, preferably with a specially designed in-line nebulizer attached to a ventilator.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: September 10, 2019
    Assignee: SAVARA INC.
    Inventor: Alan Bruce Montgomery
  • Patent number: 10407456
    Abstract: Two processes are described for preparing, in different diastereomeric purity degrees, the compound (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)-phosphoryl)amino) propanoate, having the formula given below, known as Sofosbuvir and used for the treatment of hepatitis C.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: September 10, 2019
    Assignee: QUIMICA SINTETICA, S.A.
    Inventors: Giuseppe Barreca, Marcello Rasparini, Andrea Poggiali, Luca Carcone, Roberto Rocco Tufaro, Giovanni Marras, Maurizio Taddei, Elena Cini
  • Patent number: 10407516
    Abstract: Crystalline pLNnH, useful in a pharmaceutical or nutritional composition, is disclosed.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: September 10, 2019
    Assignee: GLYCOM A/S
    Inventors: Pierre Chassagne, Nikolay Khanzhin, Agnese Maggi
  • Patent number: 10398785
    Abstract: Pharmaceutical formulations for parenteral administration comprising taxane compounds complexed with cyclodextrins and polyethylene glycol, methods of making the pharmaceutical formulations and methods of treating cancer patients using the pharmaceutical formulations.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: September 3, 2019
    Assignee: Meridian Lab
    Inventors: William W. Zhao, John K. Thottathil, Denise Smith, Xiaodong Sun, Xiangyu Dong
  • Patent number: 10392417
    Abstract: Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.±0.2 degrees 2-theta.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: August 27, 2019
    Assignee: Apicore US LLC
    Inventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Piyush D. Fadadu, Piyush B. Thumar
  • Patent number: 10392416
    Abstract: The invention relates to crystalline forms of a ?-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: August 27, 2019
    Assignee: Metro International Biotech, LLC
    Inventors: David J. Livingston, Andrew Carr, Philippe Fernandes
  • Patent number: 10376524
    Abstract: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: August 13, 2019
    Assignee: Emory University
    Inventors: Kathy P. Parker, David B. Rye, Andrew Jenkins
  • Patent number: 10377788
    Abstract: The invention provides a production method of a glycoside compound or a salt thereof, which includes subjecting a thioether compound and an alcohol compound to a coupling reaction in the presence of a halogenating agent, a desiccant and a Lewis acid, and then distillation in the presence of at least one kind of additive selected from a sulfur-containing antioxidant and a maleimide group-containing compound to give a thioether compound and a step of subjecting a glycoside compound and a thioether compound to a coupling reaction in the presence of a halogenating agent, a desiccant and a Lewis acid to give a glycoside compound. By this method, a phosphoramidite preferable for the production (synthesis) of a nucleic acid can be produced more efficiently at a high purity.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 13, 2019
    Assignee: BONAC CORPORATION
    Inventors: Eriko Aoki, Takashi Kinoshita, Akihiro Itoh, Tadaaki Ohgi
  • Patent number: 10369164
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 6, 2019
    Assignee: ABBOTT LABORATORIES
    Inventors: Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
  • Patent number: 10364265
    Abstract: Improved methods of making anhydrosugars by pyrolysis of a substrate sugar to remove at least one water molecule thereby producing a desired anhydrosugar and side products, the improvement being either 1) protecting one hydroxyl group of the substrate sugar before pyrolysis; or (2) pretreating the substrate sugar with a metal salt and optional acid before pyrolysis, wherein lower amounts of said side products are produced by said improved method.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 30, 2019
    Assignee: William Marsh Rice University
    Inventors: Li Chen, Michael S Wong, Zongchao Zhang
  • Patent number: 10363305
    Abstract: It is provided a multivalent ganglioside carbohydrate as a therapeutic cancer vaccine. The GD2 and GD3 carbohydrate conjugated disclosed are linked by a spacer to form a multimer which conserves the native structural feature of naturally occurring GD2 or GD3, the tetramer being immunogenic and elicits cytotoxic anti-gangliosides humoral and cellular responses in vivo.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: July 30, 2019
    Assignee: Horacio Url Saragovi
    Inventors: Horacio Uri Saragovi, Wenyong Tong